Wednesday, August 17, 2016 10:58:46 AM
*** Issuance of KIT-302's clinical trial full study report
*** Completion of six-month stability testing of KIT-302
*** Submission to the FDA of the New Drug Application for KIT-302
*** Initiation of a renal function clinical trial to demonstrate the
*** Beneficial effects of KIT-302 on kidney function
ADS equivalents:
Ordinary shares - 6,769,860
Series "A" warrants - 6,835,669
Series 6/14 options - 4,572.75
Series 7/14 options - 2,307.6
Series 5/15 options - 2,239.3
Series 9/15 options - 86,000
Underwriter warrants - 157,945
Emp. Incentive options - 364,068
Pre-funded warrants - 865,000 (not tradable)
Agent warrants - 141,176
Fully diluted = 15,228,838 assuming everything is exercised
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM